Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination

Journal of Cellular Physiology

Volumn 224, Issue 3, 2010, Pages 702-709

  Castaldello, Arianna ^a   Sgarbanti, Marco ^b   Marsili, Giulia ^b   Brocca Cofano, Egidio ^a   Remoli, Anna Lisa ^b   Caputo, Antonella ^a   Battistini, Angela ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 12; INTERLEUKIN 15; PLASMID DNA; TRANSACTIVATOR PROTEIN;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ARTICLE; BAGG ALBINO MOUSE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DNA BINDING; DNA IMMUNIZATION; GENE DELETION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; INOCULATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; CELL LINE; CYSTEINE ENDOPEPTIDASES; FEMALE; HIV-1; HUMANS; IMMUNIZATION; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-3; INTERFERON REGULATORY FACTOR-7; MICE; T-LYMPHOCYTES, CYTOTOXIC; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

EID: 77954576021     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22169     Document Type: Article

References (52)

1. Arya SK, Guo C, Josephs SF, Wong-Staal F. 1985. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 229:69-73. (Pubitemid 15227242)
2. Battistini A. 2009. Interferon regulatory factors in hematopoietic cell differentiation and immune regulation. J Interferon Cytokine Res 29:765-780.
3. Bedoui S, Davey GM, Lew AM, Heath WR. 2009. Equivalent stimulation of naive and memory CD8 T cells by DNA vaccination: A dendritic cell-dependent process. Immunol Cell Biol 87:255-259.
4. Berzofsky JA, Ahlers JD, Belyakov IM. 2001. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 1:209-219. (Pubitemid 33741959)
5. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M, Borsetti A, Belli R, Akerblom L, Corrias F, Butto S, Heeney J, Verani P, Titti F, Ensoli B. 1999. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5:643-650.
6. Cafaro A, Titti F, Fracasso C, Maggiorella MT, Baroncelli S, Caputo A, Goletti D, Borsetti A, Pace M, Fanales-Belasio E, Ridolfi B, Negri DR, Sernicola L, Belli R, Corrias F, Macchia I, Leone P, Michelini Z, ten Haaft P, Butto S, Verani P, Ensoli B. 2001. Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine 19:2862-2877.
7. Caputo A, Betti M, Altavilla G, Bonaccorsi A, Boarini C, Marchisio M, Butto S, Sparnacci K, Laus M, Tondelli L, Ensoli B. 2002. Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application. Vaccine 20:2303-2317. (Pubitemid 34497041)
8. Caputo A, Gavioli R, Altavilla G, Brocca-Cofano E, Boarini C, Betti M, Castaldello A, Lorenzini F, Micheletti F, Cafaro A, Sparnacci K, Laus M, Tondelli L, Ensoli B. 2003. Immunization with low doses of HIV-1 tat DNA delivered by novel cationic block copolymers induces CTL responses against Tat. Vaccine 21:1103-1111.
9. Caputo A, Gavioli R, Ensoli B. 2004. Recent advances in the development of HIV-1 Tat-based vaccines. Curr HIV Res 2:357-376. (Pubitemid 39242966)
10. Castaldello A, Brocca-Cofano E, Voltan R, Triulzi C, Altavilla G, Laus M, Sparnacci K, Ballestri M, Tondelli L, Fortini C, Gavioli R, Ensoli B, Caputo A. 2006. DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination. Vaccine 24:5655-5669.
11. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, Nason MC, Martin JE, Rucker S, Andrews CA, Gomez PL, Mascola JR,Nabel GJ,Graham BS. 2007. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25:4085-4092.
12. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. 1997. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 11:1421-1431. (Pubitemid 27421173)
13. Chatterjee-Kishore M, Kishore R, Hicklin DJ, Marincola FM, Ferrone S. 1998. Different requirements for signal and activator of transcription 1α and interferon regulatory factor-1 in the regulation of low molecular mass polypeptide 2 and transporter associated with antigen processing 1 gene expression. J Biol Chem 273:16177-16183. (Pubitemid 28311390)
14. Ciccaglione AR, Stellacci E, Marcantonio C, Muto V, Equestre M, Marsili G, Rapicetta M, Battistini A. 2007. Repression of interferon regulatory factor 1 by hepatitis C virus core protein results in inhibition of antiviral and immunomodulatory genes. J Virol 81:202-214. (Pubitemid 44975161)
15. Dovhey SE, Ghosh NS, Wright KL. 2000. Loss of interferon-g inducibility of TAP1 and LMP2 in a renal carcinoma cell line. Cancer Res 60:5789-5796.
16. Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, Li-Weber M. 2002. IFN-γ represses IL-4 expression via IRF-1 and IRF-2. Immunity 17:703-712.
17. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, Wingfield P, Gallo RC. 1993. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 67:277-287. (Pubitemid 23002988)
18. Ensoli B, Fiorelli V, Ensoli F, Cafaro A, Titti F, Butto S, Monini P, Magnani M, Caputo A, Garaci E. 2006. Candidate HIV-1 Tat vaccine development: From basic science to clinical trials. AIDS 20:2245-2261. (Pubitemid 44789527)
19. Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Monini P, Magnani M, Garaci E. 2008. The therapeutic phase I trial of the recombinant native HIV-1 Tat protein. AIDS 22:2207-2209.
20. Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R,Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E. 2009. The preventive phase I trial with the HIV-1 Tat-based vaccine. Vaccine 28:371-378.
21. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, Ensoli B. 2002. Native HIV-1Tat protein targets monocyte-derived dendritic cells and enhances theirmaturation, function, and antigen-specific T cell responses. J Immunol 168:197-206. (Pubitemid 34014119)
22. Ferrantelli F, Cafaro A, Ensoli B. 2004. Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines. Curr Opin Biotechnol 15:543-556. (Pubitemid 39551007)
23. Fragale A, Gabriele L, Stellacci E, Borghi P, Perrotti E, Ilari R, Lanciotti A, Remoli AL, Venditti M, Belardelli F, Battistini A. 2008. IFN regulatory factor-1 negatively regulates CD4+ CD25+ regulatory T cell differentiation by repressing Foxp3 expression. J Immunol 181:1673-1682.
24. Fredericksen B, Akkaraju GR, Foy E, Wang C, Pflugheber J, Chen ZJ, Gale M, Jr. 2002. Activation of the interferon-beta promoter during hepatitis C virus RNA replication. Viral Immunol 15:29-40. (Pubitemid 34273436)
25. Gabriele L, Fragale A, Borghi P, Sestili P, Stellacci E, Venditti M, Schiavoni G, Sanchez M, Belardelli F, Battistini A. 2006. IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J Leukoc Biol 80:1500-1511. (Pubitemid 44904989)
26. Garg S, Oran A, Wajchman J, Sasaki S, Maris CH, Kapp JA, Jacob J. 2003. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol 4:907-912. (Pubitemid 37098662)
27. Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, Fortini C, Cofano EB, Triulzi C, Cafaro A, Srivastava I, Barnett S, Caputo A, Ensoli B. 2008. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS. Vaccine 26:727-737.
28. Gupta RK. 1998. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 32:155-172.
29. Gurunathan S, Klinman DM, Seder RA. 2000a. DNA vaccines: Immunology, application, and optimization*. Annu Rev Immunol 18:927-974.
30. Gurunathan S, Wu CY, Freidag BL, Seder RA. 2000b. DNA vaccines: A key for inducing longterm cellular immunity. Curr Opin Immunol 12:442-447. (Pubitemid 30410351)
31. Honda K, Takaoka A, Taniguchi T. 2006. Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25:349-360. (Pubitemid 44354220)
32. Jefferson T, Rudin M, Di Pietrantonj C. 2004. Adverse events after immunisation with aluminium-containing DTP vaccines: Systematic review of the evidence. Lancet Infect Dis 4:84-90. (Pubitemid 38169274)
33. Jiang W, Ren L, Jin N. 2007. HIV-1 DNA vaccine efficacy is enhanced by co administration with plasmid encoding IFN-α. J Virol Methods 146:266-273. (Pubitemid 350026641)
34. Krieg AM. 2000. The role of CpG motifs in innate immunity. Curr Opin Immunol 12:35-43. (Pubitemid 30093448)
35. Kutzler MA, Weiner DB. 2004. Developing DNA vaccines that call to dendritic cells. J Clin Invest 114:1241-1244. (Pubitemid 40385294)
36. Lin R, Mustafa A, Nguyen H, Gewert D, Hiscott J. 1994. Mutational analysis of interferon (IFN) regulatory factors 1 and 2. Effects on the induction of IFN-β gene expression. J Biol Chem 269:17542-17549. (Pubitemid 24218035)
37. Lin R, Mamane Y, Hiscott J. 1999. Structural and functional analysis of interferon regulatory factor 3: Localization of the transactivation and autoinhibitory domains. Mol Cell Biol 19:2465-2474. (Pubitemid 29144490)
38. Lin R, Mamane Y, Hiscott J. 2000. Multiple regulatory domains control IRF-7 activity in response to virus infection. J Biol Chem 275:34320-34327.
39. Lohoff M, Mak TW. 2005. Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol 5:125-135. (Pubitemid 40208902)
40. Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, Alvarez MJ, Francavilla V, Arancio A, Paniccia G, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B, Phase I, 2009. Therapeutic trial of the HIV-1 Tat protein long term follow-up. Vaccine. 27:3306-3312.
41. Maggiorella MT, Baroncelli S, Michelini Z, Fanales-Belasio E, Moretti S, Sernicola L, Cara A, Negri DR, Butto S, Fiorelli V, Tripiciano A, Scoglio A, Caputo A, Borsetti A, Ridolfi B, Bona R, ten Haaft P, Macchia I, Leone P, Pavone-Cossut MR, Nappi F, Ciccozzi M, Heeney J, Titti F, Cafaro A, Ensoli B, 2004. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 22:3258-3269.
42. Min W, Lillehoj HS, Burnside J, Weining KC, Staeheli P, Zhu JJ. 2001. Adjuvant effects of IL- 1beta, IL-2, IL-8, IL-15, IFN-α, IFN-γ TGF-beta4 and lymphotactin on DNA vaccination against Eimeria acervulina. Vaccine 20:267-274. (Pubitemid 32905340)
43. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T. 1988. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-β gene regulatory elements. Cell 54:903-913.
44. O'Hagan DT, Valiante NM. 2003. Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2:727-735.
45. Remoli AL, Marsili G, Perrotti E, Gallerani E, Ilari R, Nappi F, Cafaro A, Ensoli B, Gavioli R, Battistini A. 2006. Intracellular HIV-1 Tat protein represses constitutive LMP2 transcription increasing proteasome activity by interfering with the binding of IRF-1 to STAT1. Biochem J 396:371-380.
46. Sasaki S, Amara RR, Yeow WS, Pitha PM, Robinson HL. 2002. Regulation of DNA-raised immune responses by cotransfected interferon regulatory factors. J Virol 76:6652-6659.
47. Sgarbanti M, Borsetti A, Moscufo N, Bellocchi MC, Ridolfi B, Nappi F, Marsili G, Marziali G, Coccia EM, Ensoli B, Battistini A. 2002. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med 195:1359-1370.
48. Sgarbanti M, Remoli AL, Marsili G, Ridolfi B, Borsetti A, Perrotti E, Orsatti R, Ilari R, Sernicola L, Stellacci E, Ensoli B, Battistini A. 2008. IRF-1 is required for full NF-kappaB transcriptional activity at the human immunodeficiency virus type 1 long terminal repeat enhancer. J Virol 82:3632-3641.
49. Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, Hida S, Suzuki G, Mitsuyama M, Shin EH, Kojima S, Taniguchi T, Asano Y. 1997. Multistage regulation of Th1-type immuneresponses by the transcription factor IRF-1. Immunity 6:673-679.
50. Tamura T, Yanai H, Savitsky D, Taniguchi T. 2008. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26:535-584.
51. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. 2001. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19:623-655. (Pubitemid 32368048)
52. Titti F, Cafaro A, Ferrantelli F, Tripiciano A, Moretti S, Caputo A, Gavioli R, Ensoli F, Robert- Guroff M, Barnett S, Ensoli B. 2007. Problems and emerging approaches in HIV/AIDS vaccine development. Expert Opin Emerg Drugs 12:23-48. (Pubitemid 46499494)